Part D Off-Label Coverage Should Not Be Limited To Compendia Lists – Lawsuit
Executive Summary
Medicare Part D drug plans should be able to consider a variety of evidence supporting off-label uses of drugs, not just the standard medical compendia list of accepted indications, a lawsuit challenging HHS' interpretation of congressional directives on this issue argues
You may also be interested in...
Legal, Legislative Quest To Expand Off-Label Part D Coverage Continues
The Medicare Rights Center is continuing a lawsuit seeking to expand coverage for off-label indications under the Medicare Part D prescription drug benefit after helping a beneficiary gain coverage of a drug to treat ovarian cancer
Legal, Legislative Quest To Expand Off-Label Part D Coverage Continues
The Medicare Rights Center is continuing a lawsuit seeking to expand coverage for off-label indications under the Medicare Part D prescription drug benefit after helping a beneficiary gain coverage of a drug to treat ovarian cancer
UnitedHealth To Rely On NCCN Compendium For Off-Label Oncology Coverage
UnitedHealth is streamlining its payment process for off-label use of oncology drugs by designating the recommendations of the National Comprehensive Cancer Network's medical compendium as its official reference